

STROBE Statement—Checklist of items that should be included in reports of cohort studies

	Item No	Recommendation	Page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract. (b) Provide in the abstract an informative and balanced summary of what was done and what was found.	1 1-2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses.	2-3
Methods			
Study design Setting	4	Present key elements of study design early in the paper.	3
Participants	5	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up. (b) For matched studies, give matching criteria .	3-4
Definition/Variables	6	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	4-5
Ascertain Mortality	7	Describe ascertainment of mortality methods if there is more than one group.	5
Statistical methods	8	(a) Describe all statistical methods, including those used to control for confounding. (b) Describe any methods used to examine subgroups and interactions. (c) Explain how missing data were addressed. (d) If applicable, explain how loss to follow-up was addressed. (e) Describe any sensitivity analyses.	5-6
Results			
Baseline characteristics	9*	Report numbers of individuals at each stage of study-eg numbers potentially eligible, examined for age, BMI, Sex, Ethnicity, education, poverty ratio, drink, physical activity, smoke, TC, TG, HbA1c, HEI, Calories, hypertension.	9-12
MHO and mortality analyses	10*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on all-cause mortality and cardiovascular mortality. (b) Summarise follow-up time (eg, average and total amount)	13-14
Stratified Analyses	11*	Observe in the stratified analyses based on age (<60), sex (Female or Male), race/ethnicity (Non-Hispanic White or	14-16

		other Hispanic), drinking status (nondrinker), physical activity (active or inactive), smoking status (never smoker or current smoker), and self-reported hypertension (no).	
<i>Sensitivity analyses</i>	12*	Give Hazard ratio (95% CIs) for MHO and MUO	16
Discussion			
Key results	13	Summarise key results with reference to study objectives.	17
Limitations	14	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss the generalisability (external validity) of the study results.	17-19
Interpretation	15	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	17-19
Generalisability	16	Discuss the generalisability (external validity) of the study results.	17-19
Other information			
Funding	17	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.	19

*Give information separately for MHO and MUO groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting.